A3P Biomedical initiates partnership with Unilabs for Stockholm3

June 16, 2022

A3P Biomedical and Unilabs have initiated a partnership for Stockholm3, A3P Biomedical's blood test for early detection of aggressive prostate cancer. Screening by Stockholm3 is requested by healthcare providers throughout Sweden. The fact that Unilabs now includes Stockholm3 in its catalogue of products will make it possible for more patients to take the test, and at the same time improve logistics for the healthcare providers.

“Stockholm3 has the potential to radically improve prostate cancer diagnostics and we would like to provide this opportunity to both patients and caregivers. The test is integrated into the patient's regular medical record and sampling can either be done at our or the care provider's own lab and follow the regular route. This means that we can offer a very attractive and flexible solution”, says Thomas Lindahl, Medical Director of Unilabs Sweden.

“We are very pleased with the Unilabs partnership. It will give men and care providers access to Stockholm3, not just in the Stockholm and Värmland regions, which is the case today. This will contribute to a faster rollout of Stockholm3 and more efficient cancer diagnostics throughout the country”, says David Rosén, CEO of A3P Biomedical.

The agreement means that care providers can order Stockholm3 through Unilab's regular catalogue in the lab portal “Labportalen” (InfoSolutions). The patient is offered sampling at one of Unilabs’ laboratories in Sweden, or at the care provider’s facilities. The sample follows the same distribution route as the other tests Unilabs offers. The Stockholm3 analysis is performed by A3P Biomedical, and the result is delivered electronically via Unilabs to the care provider.

Prostate cancer is the most common form of cancer in Sweden with approximately 2,400 deaths each year.

Stockholm3 is a blood test that radically improves early detection of aggressive prostate cancer and reduces the number of unnecessary prostate biopsies, compared to PSA which is the traditional blood test for detecting prostate cancer. Stockholm3 has very strong clinical evidence based on studies including more than 75,000 men and has been in clinical use in Sweden and Norway since 2017.

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com 

About Stockholm3

Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml.  Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values.  Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com.

About prostate cancer

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

Press contact:
Cecilia Edström
cecilia.edstrom@a3p.com
+46 72 226 2328